US2006281166A1PendingUtilityA1
Stabilization of T4 endonuclease V
Est. expirySep 24, 2021(expired)· nominal 20-yr term from priority
C12N 9/96C12Q 1/37C12Q 1/44
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides T4 endonuclease V compositions that exhibit enhanced stability, including stability at non-refrigerated temperatures, through reduced activity of cryptic proteases. Methods for detecting cryptic protease activity and methods for reducing such activity are also provided.
Claims
exact text as granted — not AI-modified1 . A composition comprising T4 endonuclease V wherein:
(a) the composition has T4 endonuclease V activity; and (b) a sample of the composition when tested for protease activity using a labeled reporter peptide whose amino acid sequence is Pro Leu Ser Arg Thr Leu Ser Val Ala Ala Lys (SEQ ID NO:1) gives a percentage of degraded reporter peptide of less than 10 percent, where the test for protease activity comprises the steps of: (i) preparing a test solution comprising an aqueous buffer, a sample of the composition, and the labeled reporter peptide, where the concentration of the T4 endonuclease V in the test solution is 0.095±0.05 mg/ml; (ii) incubating the test solution at 25° C. for a period of 7 days; and (iii) determining the percentage of degraded reporter peptide after step (ii) by subjecting at least a portion of the test solution to a peptide separation procedure and determining the percentage of degraded reporter peptide by densitometry.
2 . The composition of claim 1 wherein a sample of the composition when tested for storage stability at 25° C. for a test period of four weeks retains over that period at least 10 percent of its T4 endonuclease V activity at the beginning of the period.
3 . The composition of claim 1 wherein a sample of the composition when tested for storage stability at 25° C. for a test period of six months retains over that period at least 10 percent of its T4 endonuclease V activity at the beginning of the period.
4 . A composition comprising T4 endonuclease V wherein:
(a) the composition has T4 endonuclease V activity; and (b) the composition shows no difference by statistical analysis (p>0.05) in specific T4 endonuclease V activity between storage for one week at 4° C. and storage for one week at 25° C.Join the waitlist — get patent alerts
Track US2006281166A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.